4D Molecular (FDMT) Therapeutics announced the appointment of Kristian Humer as CFO. Humer will lead the company’s financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience spanning corporate finance, strategic operations and healthcare investment banking. During his tenure at Citi, he held progressively senior roles, culminating as Managing Director in Citi’s Healthcare Investment Banking Group, where he worked from 2010 to 2021.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position
- 4D Molecular price target raised to $32 from $26 at RBC Capital
- 4D Molecular price target lowered to $33 from $38 at Barclays
- 4D Molecular Therapeutics Reports Strategic Gains in Q3 2025
- 4D Molecular sees cash runway into 2H28